Clinicopathological characteristics and prognosis of 77 cases with type 3 gastric neuroendocrine tumours

Table 3 Univariate analysis for prognosis

	HR (95%CI)	P value
Age
≤ 45 years old	1
> 45 years old	1.92 (0.61-6.06)	0.264
Gender
Male	1
Female	0.87 (0.32-2.41)	0.794
Size
< 2 cm	1
≥ 2 cm	10.07 (2.27-44.67)	0.002
Site
Cardia	1
Fundus/body	0.88 (0.20-3.98)	0.871
Antrum	5.817 (0.81-42.01)	0.081
Number
1	1
≥2	0.33 (0.04-2.48)	0.279
EA
Polyp	1
Bulge	2.37 (0.45-12.54)	0.312
Ulcer	4.20 (1.33-13.23)	0.014
Infiltration
M/SM	1
MP	8.57 (0.77-95.33)	0.081
Beyond MP	3.02 (0.19-48.42)	0.436
Grade
G1	1
G2	9.77 (1.22-78.10)	0.032
G3	61.68 (7.01-542.62)	< 0.001
Stage
I-III	1
IV	11.15 (3.13-39.66)	< 0.001
Treatment
ER or surgery	1
SSA	4.65 (0.47-45.57)	0.187
CBCT	11.38 (3.16-40.93)	< 0.001

EA: Endoscopic appearance; M: Mucosa; SM: Submucosa; MP: Muscularis propria; ER: Endoscopic resection; SSA: Somatostatin analogs; CBCT: Chemotherapy-based comprehensive treatment.